What is Elasmogen?
Elasmogen is a privately-held biopharmaceutical company established in 2016 and based in Aberdeen, Scotland. The company is dedicated to advancing a pipeline of innovative soloMER products targeting significant unmet medical needs in solid-tumor cancers, systemic inflammatory diseases, and inflammatory conditions of the gut. Its strategic location within Scotland's biologics cluster provides a fertile ground for growth and collaboration in the life sciences sector.
How much funding has Elasmogen raised?
Elasmogen has raised a total of $13.9M across 3 funding rounds:
Unspecified
$1.5M
Private Equity
$2.6M
Other Financing Round
$9.9M
Unspecified (2017): $1.5M with participation from Scottish Investment Bank and Deepbridge Capital
Private Equity (2020): $2.6M led by Deepbridge Capital
Other Financing Round (2022): $9.9M supported by BFG International
Key Investors in Elasmogen
BFG International
BFG International is a manufacturing company established in 1975, offering composite solutions across various industries, including renewable energy and automotive. Their participation in Elasmogen's funding round indicates a potential interest in the broader applications or manufacturing aspects of biopharmaceutical advancements.
Scottish Investment Bank
The Scottish Investment Bank, part of Scottish Enterprise, is a national economic development agency supporting businesses in Scotland. Their backing of Elasmogen highlights a commitment to fostering innovation and growth within the Scottish biopharmaceutical sector.
Deepbridge Capital
Deepbridge Capital is a private investor network specializing in innovative Life Sciences and Technology companies, providing access to EIS-qualifying investments. Their continued support for Elasmogen signifies a belief in the company's early-stage potential and its unique soloMER technology.
What's next for Elasmogen?
With a significant enterprise-level funding context, Elasmogen is poised for accelerated development and potential commercialization of its soloMER technology. The recent strategic investment suggests strong confidence from backers in the company's therapeutic approach and market potential. Future endeavors will likely focus on advancing clinical trials, expanding the product pipeline, and potentially forging strategic partnerships to bring its novel cancer and inflammatory disease treatments to patients.
See full Elasmogen company page
